IN BRIEF: Haleon acquires remaining 12% stake in Chinese joint venture

Related news

Haleon PLC - Weybridge, Surrey-based consumer healthcare firm that spun out of GSK PLC in 2022 - Agrees to acquire the remaining 12% stake in Tianjin TSKF Pharmaceutical Co Ltd, its joint venture in China, following its acquisition of a further 33% interest in December 2024. The remaining stake will be bought from partner Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd for a total of ¥1.62 billion, around $221 million. TSKF will become a wholly-owned subsidiary of Haleon.

The purchase will be funded via Haleon’s existing cash resources and new local-currency debt and is expected to close within the next three months, it said.

Current stock price: 379.40 pence, up 0.1% in London on Tuesday morning

12-month change: up 17%

Copyright 2025 Alliance News Ltd. All Rights Reserved.

Bids, mergers and takeovers

Ways to help you invest your money

Our investment accounts

Put your money to work with our range of investment accounts. Choose from ISAs, pensions, and more.

Need some investment ideas?

Let us give you a hand choosing investments. From managed funds to favourite picks, we’re here to help.

Read our expert tips and insights

Our investment experts share their knowledge on how to keep your money working hard across the markets.